Quasi‑atrophic scar (keloid) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quasi‑atrophic scar (keloid) is a type of abnormal scar that grows beyond the boundaries of the original wound and never regresses. Although the term “quasi‑atrophic” is sometimes used to describe a keloid that appears slightly raised but flatter than classic keloids, the underlying pathology is the same: excess collagen deposition during the healing process.

• Who it affects: People of any age can develop keloids, but they are most common between the ages of 10‑30 years.
• Ethnicity: Individuals with darker skin tones (African, Hispanic, Asian, and Native American descent) have a 4‑ to 15‑fold higher risk than those with lighter skin.
• Gender: Slight female predominance has been reported, possibly related to hormonal influences.
• Prevalence: Estimates range from 5–15 % of the general population, rising to >20 % in high‑risk ethnic groups (Mayo Clinic, 2023).

Keloids can develop after any type of skin injury—surgery, acne, piercings, burns, or even minor scratches—and they tend to recur after removal.

Symptoms

Keloids have a fairly characteristic appearance, but symptom severity varies widely. Common features include:

1. Raised, thickened scar tissue – extends beyond the original wound margin, often 1‑5 mm (or more) above skin level.
2. Texture – firm or rubbery to the touch; may feel smooth or nodular.
3. Color – pink, red, brown, or hyperpigmented; may become less erythematous over time.
4. Itching or pruritus – reported in up to 70 % of patients (Cleveland Clinic, 2022).
5. Pain or tenderness – especially if the keloid is under tension or pressed against clothing.
6. Mobility limitation – when located over joints (e.g., shoulder, chest, knee), the scar can restrict range of motion.
7. Psychological impact – embarrassment, anxiety, or reduced quality of life are common, particularly for conspicuous facial or chest keloids.

Causes and Risk Factors

Keloids result from an exaggerated wound‑healing response. The precise biochemical cascade is not fully understood, but several mechanisms are implicated:

• Excess fibroblast activity – leads to over‑production of type III collagen early, later replaced by type I collagen.
• Elevated Transforming Growth Factor‑β (TGF‑β) – stimulates fibroblast proliferation and collagen synthesis.
• Reduced collagen‑degrading enzymes (matrix metalloproteinases) – prevents normal scar remodeling.

Risk factors that increase the likelihood of a quasi‑atrophic/keloid scar include:

• Genetic predisposition (first‑degree relatives with keloids).
• Dark skin pigmentation.
• Age 10‑30 years (peak collagen synthesis).
• Hormonal influences – higher incidence during puberty and pregnancy.
• Location of injury – chest, shoulders, upper back, earlobes, and cheeks are “keloid‑prone” sites.
• Type of injury – surgical incisions, deep dermal wounds, burns, and piercings.
• Delayed wound healing or infection.

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. However, certain tests help rule out other conditions or guide treatment planning.

Clinical assessment

• Inspection of scar size, shape, color, and relationship to the original wound.
• Palpation for firmness, tenderness, and depth.
• Assessment of functional limitation (e.g., range‑of‑motion testing).

Adjunctive investigations

1. Dermatoscopy – visualises vascular patterns that differ from hypertrophic scars.
2. High‑frequency ultrasound – measures scar thickness and helps monitor treatment response.
3. Biopsy (rare) – performed when the diagnosis is uncertain; histology shows thick, hyalinized collagen bundles extending beyond the dermis.
4. Allergy testing – considered if an allergic reaction to a suture or tattoo pigment is suspected.

Treatment Options

Because keloids have a high recurrence rate (up to 70 % after excision alone), a multimodal approach is usually recommended. Treatment choices depend on scar size, location, symptom severity, and patient preference.

First‑line non‑invasive therapies

• Silicone gel sheeting or silicone ointment – applied 12–24 h/day for 2–6 months; reduces erythema and height in 40‑60 % of cases (NIH, 2022).
• Pressure therapy – custom‑fit garments exert 24–30 mmHg; most effective for ear‑lobes and chest keloids.
• Topical corticosteroids (e.g., clobetasol propionate 0.05 %) – may soften early lesions, though penetration is limited.

Injection‑based therapies

1. Intralesional corticosteroids (triamcinolone acetonide 10‑40 mg/mL) – the most widely used; injected every 4–6 weeks for 3‑6 sessions. Reduces volume by 30‑50 % on average.
2. 5‑Fluorouracil (5‑FU) – anti‑metabolite that inhibits fibroblast proliferation; often combined with steroids for synergistic effect.
3. Bleomycin – cytotoxic agent used in refractory cases; limited by potential ulceration.
4. Verapamil – calcium‑channel blocker; modest results, generally adjunctive.

Procedural options

• Laser therapy – Pulsed‑dye laser (PDL) or CO₂ laser improves redness and flattening; multiple sessions required.
• Cryotherapy – Freezing the scar with liquid nitrogen; works best for small, superficial keloids.
• Radiation therapy – Low‑dose external beam or brachytherapy after surgical excision; reduces recurrence to <10 % but reserved for high‑risk cases due to malignancy concerns.
• Surgical excision – Removes bulk of scar tissue; must be combined with adjuvant therapy (radiation, steroids, or silicone) to prevent regrowth.
• Laser‑assisted drug delivery – Using ablative lasers to enhance penetration of topical agents.

Emerging and adjunctive treatments

1. Botulinum toxin (Botox) – Decreases tension on the scar; early studies show 20‑30 % reduction in size.
2. Platelet‑rich plasma (PRP) – Autologous growth factors may modulate fibroblast activity; data are mixed.
3. Intralesional interferon‑α2b – Immunomodulatory; limited to refractory cases.

Lifestyle and self‑care measures

• Keep the scar moisturized with non‑comedogenic emollients.
• Avoid sun exposure; use SPF 30+ sunscreen to prevent hyperpigmentation.
• Do not pick, scratch, or massage aggressively—this can trigger further collagen production.

Living with Quasi‑atrophic Scar (keloid)

Managing a keloid is a long‑term commitment. Below are practical tips for daily life:

• Skin hygiene: Gentle cleansing with fragrance‑free cleansers reduces irritation.
• Silicone therapy adherence: Apply silicone sheet for at least 12 h/day; replace weekly.
• Protective clothing: Loose‑fitting garments over affected areas prevent friction.
• Emotional support: Consider counselling or support groups; keloids can affect self‑esteem.
• Regular follow‑up: Schedule appointments every 3‑6 months to monitor growth or recurrence.
• Physical therapy: If the scar limits movement, a therapist can prescribe stretching exercises.

Prevention

While not all keloids are preventable, risk can be reduced with proactive measures:

1. Optimize wound care – Clean wounds promptly, keep them moist (e.g., petroleum jelly), and use sterile dressings.
2. Avoid unnecessary skin trauma – Delay elective piercings or tattoos until adulthood if you have a strong family history.
3. Use prophylactic silicone – Apply silicone sheets within the first few weeks after surgery or injury in high‑risk individuals.
4. Consider pressure garments after high‑risk surgeries (e.g., chest wall procedures).
5. Discuss with surgeons – Request a minimally invasive technique and intra‑operative corticosteroid injection if you’re prone to keloids.

Complications

If left untreated or inadequately managed, keloids can lead to several issues:

• Functional impairment – Restricted joint movement or difficulty wearing clothing.
• Chronic pain or pruritus – May interfere with sleep and daily activities.
• Secondary infection – Breakdown of overlying skin, especially after trauma.
• Psychological distress – Anxiety, depression, and social withdrawal.
• Hypertrophic changes – In rare cases, keloids can become extremely bulky, causing disfigurement.

When to Seek Emergency Care

---

Sources: Mayo Clinic. Keloid Scars: Diagnosis and Treatment. 2023; CDC. Skin Injury and Healing. 2022; NIH National Library of Medicine. Keloid Pathophysiology. 2022; Cleveland Clinic. Keloid Management Guidelines. 2022; World Health Organization. Skin Health Fact Sheet. 2021; Journal of Dermatologic Surgery & Oncology. “Combination Intralesional Therapy for Keloids,” 2023.

```